Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy

Current Oncology

Volumn 21, Issue 2, 2014, Pages

  Wong, P ^a   Han, K ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Li fraumeni; Oncology; P53; Radiation; Toxicity

Indexed keywords

DACARBAZINE; DOXORUBICIN; ERIBULIN; GEMCITABINE; IFOSFAMIDE; PROTEIN P53; RADIOACTIVE IODINE;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BILIARY STENT; BONE LESION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FAMILIAL CANCER; FEMALE; GENETIC ANALYSIS; GERMLINE MUTATION; HUMAN; METASTASIS; MIDDLE AGED; PAIN; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; RADIATION TOXICITY; SALPINGOOOPHORECTOMY; SMALL INTESTINE OBSTRUCTION; THYROID CANCER; THYROIDECTOMY; TOXICITY; UTERUS SARCOMA;

EID: 84898797335     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1841     Document Type: Article

References (29)

1. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250-6.
2. Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni syndrome. In: Pagon RA, Adam MP, Bird TD, et al., eds. GeneReviews. Seattle, WA; University of Washington; 1993. [Available online at: http://www.ncbi.nlm.nih.gov/books/NBK1311/; cited February 21, 2014]
3. Chompret A, Brugieres L, Ronsin M, et al. p53 Germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000;82:1932-7.
4. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010;47:421-8.
5. World Health Organization, International Agency for Research on Cancer (iarc). IARC TP53 database [Web resource]. Release R16. Lyon, France: iarc; 2012. [Available at: http://p53.iarc.fr/DevelopmentHistory.aspx#AccordionPane2012; cited February 21, 2014]
6. Boyle JM, Spreadborough A, Greaves MJ, Birch JM, Varley JM, Scott D. The relationship between radiation-induced G(1) arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. Br J Cancer 2001;85:293-6.
7. De Moura J, Kavalec FL, Doghman M, et al. Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to dna damage. Int J Oncol 2010;36:983-90.
8. Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Buhairi M, Al-Hadyan K, Al-Rajhi N. Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007;68:229-35.
9. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009;92:299-309.
10. Tan XL, Popanda O, Ambrosone CB, et al. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 2006;97:255-62.
11. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012;13:65-77.
12. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997;57:3245-52.
13. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
14. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010;5:104.
15. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238-42.
16. Nutting C, Camplejohn RS, Gilchrist R, et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 2000;12:300-4.
17. Agir H, MacKinnon C, Tan ST. Li-Fraumeni syndrome: a case with 4 separate primary sarcomas and 5 sequential free flaps in the maxillofacial region. J Oral Maxillofac Surg 2008;66:1714-19.
18. Salmon A, Amikam D, Sodha N, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline "de-novo" TP53 mutation. Clin Oncol (R Coll Radiol) 2007;19:490-3.
19. Henry E, Villalobos V, Million L, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Cancer Netw 2012;10:939-42.
20. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
21. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
22. Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol 2011;21:43-50.
23. Kemp CJ, Wheldon T, Balmain A. p53 Deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet 1994;8:66-9.
24. United Kingdom, Department of Health, Cancer Policy Team. Radiotherapy Services in England 2012. London, U.K.: National Radiotherapy Implementation Group; 2012.
25. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129-37.
26. Tyldesley S, Delaney G, Foroudi F, Barbera L, Kerba M, Mackillop W. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys 2011;79:1507-15.
27. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. globocan 2008: Cancer Incidence and Mortality Worldwide [Web resource]. Ver. 2.0. Lyon, France: International Agency for Research on Cancer; 2010.
28. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Ver. 4.2013. Fort Washington, PA: nccn; 2013. [Available online at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (free registration required); cited February 21, 2014]
29. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011;12:559-67.